Objectives: Based on excellent data of Results of the Pivotal phase II study (Younes et al.,J Clin Oncol. 2012 Jun 20;30(18):2183-9), the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved BV for the treatment of patients with HL who have either failed autologous stem cell (ASCT) or had at least two prior multi-agent chemotherapy regimens and who are not candidates for ASCT. Since the approval several study groups published the results of their experience in treating refractory/relapsed HL patients with BV. This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin lymphoma (HL). Patients and methods: A systematic literature search was performed and included studies published from 1st January 2012 to 1st July 2015 investigating BV in patients with relapsed/refractory HL. Data was extracted and reviewed by two investigators then analyzed using the comprehensive meta-analysis version 3 software. Heterogeneity of studies was identified according to I2 value. Studies are regarded homogenous if I2 ≤ 25% and the fixed effect model of meta-analysis is used. Results: 22 out of 4048 screened records met the eligibility criteria. These records included 903 patients. The median age of the cohort was 31 year (range: 26-45). 86% received ≥ 3 previous lines of systemic therapy. 529 (58.7%) and 232 (25.7%) underwent high dose chemotherapy and autologous and/or allogeneic stem transplantation prior of BV respectively. The overall response rate to BV was 62.7% (range: 30-100%)(Fig.1). The complete response, partial response, stable disease and progressive disease rates were 31.8% (Fig. 2), 35.1%, 19.5% and 11.7% respectively. The one year progression free survival and estimated one year overall survival were 47.6% (Fig. 3) and 79.5% (Fig. 4) respectively. Additional fixed effect model meta-analysis showed similar results (difference: <2%) except for progressive disease (difference: 9.3%) and progression at one year (difference: 5.2%) (Table 1). Conclusion: In this largest published pooled cohort BV produces high responses with encouraging progression free and overall survival in relapsed/refractory HL patients. Our results enhance the role of BV in heavily pretreated HL patients.